OLD Mission Capital LLC Makes New $1.54 Million Investment in Hologic, Inc. (NASDAQ:HOLX)

OLD Mission Capital LLC acquired a new stake in Hologic, Inc. (NASDAQ:HOLX) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 21,347 shares of the medical equipment provider’s stock, valued at approximately $1,539,000.

A number of other hedge funds have also modified their holdings of the business. Brooklyn Investment Group raised its position in Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 145 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 159 shares during the last quarter. Trivant Custom Portfolio Group LLC increased its position in Hologic by 2.1% in the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock valued at $602,000 after acquiring an additional 169 shares during the period. UMB Bank n.a. raised its stake in Hologic by 4.1% during the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider’s stock valued at $343,000 after acquiring an additional 188 shares during the last quarter. Finally, Capital Investment Counsel Inc lifted its position in Hologic by 3.6% during the 4th quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider’s stock worth $413,000 after acquiring an additional 200 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Price Performance

Hologic stock opened at $60.56 on Thursday. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The firm’s 50-day simple moving average is $64.69 and its 200 day simple moving average is $72.88. Hologic, Inc. has a 52 week low of $59.53 and a 52 week high of $84.67. The firm has a market capitalization of $13.59 billion, a PE ratio of 19.10, a P/E/G ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on HOLX shares. Citigroup dropped their target price on Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Morgan Stanley lowered their target price on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Finally, BNP Paribas raised shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Hologic presently has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.